The optimal conditioning regimen for allogeneic BMT for hematological malignancies is still to be determined. We used a conditioning regimen including high-dose Ara-C (HDAC)/CY/TBI for patients at high risk for leukemic relapse (regimen A, Ara-C 3 g/m 2 every 12 h for six doses followed by CY 45 mg/kg for 2 days and TBI 13.2 Gy in eight fractions) and a standard CY/TBI conditioning regimen for patients at low risk (regimen B, CY 60 mg/kg for 2 days and TBI 13.2 Gy in eight fractions). We analyzed 55 patients treated with regimen A (group A) and 36 patients with regimen B (group B). Relapse rates (10.9% in group A, 2.9% in group B, P = 0.23), 5-year overall (53.2% in group A and 60.8% in group B, P = 0.26) and disease-free (47.7% in group A and 60.8% in group B, P = 0.11) survival rates were not significantly different between these groups, although group A consisted of high-risk patients. Regimen-related toxicities were not significantly different between the two groups. This result suggests that adding HDAC to CY/TBI conditioning regimen may reduce leukemic relapse and improve survival without increasing regimen-related toxicities. Keywords: allogeneic BMT; conditioning; toxicity; Ara-C; relapse Allogeneic BMT has been used effectively to treat a variety of hematologic malignancies.
mens, [6] [7] [8] but no study so far has shown a significant advantage of other regimens over CY/TBI.
At the University of Wisconsin-Madison, we have used the standard conditioning regimen of CY/TBI for patients at low risk for leukemic relapse after BMT, and an intensified conditioning regimen of HDAC/CY/TBI for patients at higher risk, based on the hypothesis that the increased antitumor activity of HDAC would decrease the expected high incidence of leukemic relapse in patients with poor prognostic factors. In this article we summarize a prospective comparison of results obtained with these two regimens.
Patients and methods
All patients who underwent matched related allogeneic bone marrow transplantation at the University of Wisconsin-Madison between February 1990 and March 1997 with the diagnosis of AML, ALL, CML or MDS were entered in this study. Patients were assigned to a regimen according to their risk for leukemic relapse after BMT. Patients with the following diagnosis were considered to be at higher risk for leukemic relapse:
(1) AML/MDS: second or subsequent complete remission (CR); first or subsequent relapse; primary refractory AML; high-risk cytogenetic features including deletions of chromosome 5 or 7 (Ϫ5, Ϫ7) or multiple cytogenetic abnormalities; preceding MDS, persistent cytogenetic abnormalities, or with central nervous system (CNS) involvement. CR was defined as follows: less than 5% blasts in bone marrow aspiration specimens when bone marrow recovered from suppression. (2) ALL: age of Ͻ2 or Ͼ50 years; high WBC count at presentation (Ͼ25 000/l); high risk cytogenetic abnormalities such as t (9, 22) , t (8, 14) , or t(4,11); second or subsequent CR; first or subsequent relapse; primary refractory ALL; ALL with myeloid features; ALL which required more than one induction cycle to induce a CR or more than 4 weeks before achieving a CR. ALL patients lacking these high-risk features were not transplanted in first CR, and if they relapsed, they were transplanted with regimen A; consequently, all ALL patients were transplanted with regimen A. (3) CML: in accelerated phase (AP) or in blastic phase (BP).
The high-risk regimen (regimen A) was as follows: Ara-C 3 g/m 2 every 12 h i.v. for six doses (days Ϫ10 to Ϫ8, total dose 18 g/m 2 ), CY 45 mg/kg once daily i.v. for two doses (days Ϫ7, Ϫ6, total dose 90 mg/kg), and TBI 13.2 Gy in eight fractions over 4 days (days Ϫ4 to Ϫ1). The low-risk regimen (regimen B) consists of: CY 60 mg/kg once daily i.v. for two doses (days Ϫ7, Ϫ6, total dose 120 mg/kg), and TBI 13.2 Gy in eight fractions over 4 days (days Ϫ4 to Ϫ1). BM was infused on day 0. Patients with high-risk features (group A) were transplanted using regimen A whereas those without these features (group B) were transplanted using regimen B. Regimen-related hepatotoxicity and nephrotoxicity were analyzed by reviewing serial liver function tests and creatinine values, respectively. Other regimen-related toxicities were analyzed using Bearman's criteria. 9 Most of the statistical analyses were performed using Prism 2.01 for Windows 95 (GraphPad Software, San Diego, CA, USA). P values were obtained using Fisher's exact test 10 or MannWhitney test 11 (liver function tests and creatinine analyses only). Survival curves were drawn using the method of Kaplan-Meier, 12 and P values of survival curves were obtained using a log-rank test.
11 A two-sided P value of Ͻ0.05 was considered significant. Data were analyzed as of October 1997.
Results
Patient characteristics are summarized in Table 1 . Group A consisted of patients at high risk for leukemic relapse after BMT. Eighteen patients with acute leukemia in first CR were included in this group. All of them had either ALL or AML with high-risk features. In contrast, acute leukemia patients in first CR in group B lacked high-risk features. As shown in Table 2 , the incidence of acute and chronic GVHD was not significantly different between the two groups. Relapse was observed in 5/46 patients in group A and in 1/35 in group B, P = 0.23. Graft failure or rejection occurred in 3/46 patients in group A and 3/35 in group B, P = 1.0 (patients who died before day 30 were excluded from these analyses). There was no statistically significant difference in relapse rate between the two groups, despite the fact that group A consisted of patients at higher risk for leukemic relapse. The relapse rate in the group of patients with high-risk leukemia treated by regimen A was relatively low compared to the relapse rates in similar groups of patients in other studies, which range between 15 and 77%. [13] [14] [15] [16] [17] [18] The relapse rate in the low-risk group was comparable to those in previous reports, which are 7-35%. 2, 19, 20 Regimen-related hepatotoxicity and nephrotoxicity were evaluated by review of serial liver function tests and creatinine values, respectively. Values obtained before BMT, on days 10 and 20, and the highest values during the posttransplant period were analyzed using the Mann-Whitney test. 11 As shown in Figure 1 , none of the liver function tests or creatinine values showed significant differences between the two groups. Veno-occlusive disease (VOD) of the liver was seen in only one patient in group A, and in none of the patients in group B. Other regimen-related toxicities, including cardiac, bladder, pulmonary, CNS, gastrointestinal (GI), and oral (stomatitis) toxicities were analyzed using Bearman's criteria. 9 None of these analyses showed significant differences (Table 3A) . No significant increases in infections were seen in group A compared to group B (Table 3B) .
Fifty-six patients are alive, with a mean observation time of 36.6 months (range 2.2-75.9 months). Figure 2a shows disease-free survival (DFS) and Figure 2b shows overall survival (OS) for all patients in group A and group B. The differences between group A and B in both figures were analyzed by the log-rank test. No significant differences in overall or disease-free survival between the two groups were found. Early deaths, defined as occurring within 30 days of transplant, were seen more in group A, although this difference did not reach statistical significance (Table  4A ). The nine patients who died before day 30 are shown in Table 4B . Most of the early deaths were attributed to advanced disease status at the time of BMT, rather than to regimen-related toxicities. 
Discussion
Various conditioning regimens for BMT in hematologic malignancies have been developed and investigated. Several reports have compared different conditioning regimens. 21 Disease relapse has been a significant cause of failure after BMT using the standard CY/TBI regimen. 13, 14, 19 Therefore, intensification of the conditioning regimen has been investigated in multiple studies. Studies in which etoposide was substituted for CY resulted in acceptable toxicity and outcomes comparable to CY/TBI. 5 Ara-C/TBI regimens have also been evaluated, and reported outcomes were similar to those obtained with the CY/TBI regimen. [22] [23] [24] In some reports comparing HDAC/TBI regimens with CY/TBI regimens, no advantage in using the HDAC/TBI regimens was demonstrated, 25, 26 while other reports showed that the HDAC/TBI regimens were more toxic. 27 Some investigators reported that HDAC-containing regimens were highly effective in reducing relapse rate after BMT. For example, Champlin et al 28 showed that a regimen containing HDAC had good anti-leukemic activity with an acceptable toxicity profile. However, Weyman et al 29 reported that although HDAC-containing regimen was effective in reducing leukemic relapse, gain in anti-leukemic effect was offset by increased toxicity. Gordon et al 30 reported that they did not observe much increase in acute toxicity in children treated with a HDAC-containing regimen, but that late toxicities were serious, although these toxicities may have been caused by cranial irradiation. In addition, Gale and the UCLA group [31] [32] [33] tested the SCARI regimen (Ara-C, 6-thioguanine, daunorubicin, CY and TBI) in the 1970s and found that this regimen had a low leukemic relapse rate but was complicated by an increased infection rate. Thus, the existing literature does not provide convincing evidence for the use of Ara-C in place of CY.
The combination of Ara-C and CY/TBI was investigated at several transplant centers. Messner et al 34 used low-dose Ara-C/CY/TBI, and found that this regimen was well tolerated. Forman et al 35 also used a combination of low-dose Ara-C and CY/TBI, and reported a 60% long-term survival. Investigators at Rosewell Park Memorial Institute showed that adding HDAC to CY/TBI did not confer any anti-leukemic benefit, but they observed increased toxicity, particularly the incidence of fungal infections. 36 A study from Seattle 37 used HDAC/TBI with or without additional CY (60 mg/kg) and found no difference between these two conditioning regimens. Their overall results with HDAC containing regimen were comparable to historical results in Seattle using CY/TBI. Several recent trials using HDAC, CY and TBI have demonstrated results comparable to those obtained with CY/TBI. 8, 38 In contrast, Broun et al 39 found that conditioning with HDAC, CY and TBI resulted in a high incidence of pulmonary toxicity. Similarly, Petersen et al 40 reported excessive pulmonary toxicity. However, in their regimen, Ara-C and CY were given simultaneously as a continuous infusion, which may explain the excessive toxicity observed. Armitage et al 41 utilized the same regimen that we report in this study and they reported excessive toxicity in a group of heavily pretreated patients. At the University of Wisconsin, when the conditioning regimen consisting of HDAC, CY and TBI was initially used, CY was given at a dose of 60 mg/kg on 2 consecutive days, concomitantly with HDAC. Excessive cardiac toxicity was observed with this regimen. 42 Although many of these studies indicated the superior anti-leukemic activity of HDAC, addition of HDAC to the CY/TBI regimen did not confer overall advantage, because any anti-leukemic activity of HDAC was offset by increased toxicity.
More recently, a French group compared various conditioning regimens for relapsed childhood acute lymphocytic leukemias, including a HDAC-containing regimen, TAM (TBI/Ara-C/melphalan), which showed the lowest relapse rate among the three regimens and a trend toward improved survival. 15 This study indicated that if HDAC was given in a manner which does not increase regimenrelated toxicity, it may give additional benefit in reducing the rate of leukemia relapse.
In our study, group A, which consisted of high-risk patients, had OS and DFS comparable to group B, low-risk group. Group A patients were conditioned with regimen A, HDAC/CY/TBI, whereas group B patients were conditioned with regimen B, CY/TBI. The results of group B regarding OS and DFS are comparable with the results published elsewhere. 2, 19, 20 It is of note that the relapse rate in group A was at the same level as in group B. This result suggests that the addition of HDAC to conditioning regimen, given in the manner described here for regimen A, may alleviate the adverse prognostic impact of high-risk features in leukemia patients undergoing allogeneic BMT.
Previously reported studies have indicated that addition of Ara-C to the conditioning regimen increased pulmonary toxicity 25, 30, 34, 39, 40 and infections, 6, 8 particularly by fungus 25, 31, 36 or Streptococcus viridans. 43 In our study, however, we did not observe any of these excessive tox-icities when comparing results in the HDAC group to those in the group without addition of HDAC. Regarding the pulmonary toxicity, most of the studies which showed excessive pulmonary toxicity used eight to 12 doses of Ara-C as opposed to six doses in our current study. Similarly, there have been reports of excessive neurological toxicity with HDAC, but we did not observe a significant increase in neurological toxicity in the HDAC group. The Ara-C dose of 18 g/m 2 in our regimen is significantly lower than the dose at which neurological toxicity is commonly seen. 44 Casper et al 45 used 3 g/m 2 × 6 doses of HDAC, and they reported good results in unrelated BMT in children. Also, as described before, excessive cardiac toxicity was seen with HDAC/CY/TBI regimen at the University of Wisconsin when the dose of CY was 60 mg/kg for 2 days and CY was given concomitantly with HDAC. Subsequently, the dose of CY was decreased to 45 mg/kg given on 2 consecutive days and CY was given after HDAC. We did not observe excessive cardiac toxicity after these modifications. In addition, Gassmann et al 46 reported that etoposide and Ara-C are both inferior to CY in facilitating engraftment. Our current study, however, did not show any evidence of increased graft failure, despite CY being decreased to 90 mg/kg.
In summary, the HDAC-containing regimen described in this study seems promising for decreasing leukemic relapse after BMT without an apparent increase of regimen-related toxicity. In fact, the use of an intensified Ara-C preparative regimen may have eliminated the expected difference in disease-free survival between high-risk and low-risk leukemia patients in our study. Prospective randomized studies are warranted to confirm these observations.
